Non-Pharmaceutical Grade Drug Discovery Services for Common Bacteria Infection Research
Creative Biolabs provides specialized non-pharmaceutical-grade drug discovery services for clients researching common bacterial infections such as Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, and Klebsiella. Our team is dedicated to the search and discovery of new anti-bacterial infection strategies and non-pharmaceutical grade drugs through multidisciplinary and systems biology research.
Process for Non-Pharmaceutical Grade Drug Discovery Services
-
Knowledge of the infection information of the target strain, such as infection site, symptoms, etc.
-
Strain identification and infection analysis. We first conduct a detailed identification of the strain provided by the client, including the species classification, genome analysis, etc., and further analyze the infection situation in depth.
-
Drug screening and assessment. After understanding the characteristics of the strain and the infection, we proceed with a large-scale drug screening to identify drugs that are effective against the bacteria. Detailed evaluation of the screened drugs is also carried out.
-
Efficacy testing and safety profiling. After screening and evaluation, we perform efficacy testing of the drug in vitro and in animal models to confirm its therapeutic efficacy against infections. In parallel, we perform the safety assessment of the drug.
-
Results and report delivery. Upon completion of the above steps, we deliver detailed non-pharmaceutical drug discovery reports to clients, including strain identification results, infection analysis, drug screening and evaluation results, efficacy testing and safety assessment results.
Strengths of Drug Discovery Services for Common Bacteria Infection Research at Creative Biolabs
-
Multi-level screening. We employ multiple screening methods, including computer-aided drug design, virtual screening, and structure-activity relationship-based screening, to ensure the discovery of non-pharmaceutical-grade drugs with potential efficacy against bacterial infections.
-
Data processing and integration. We integrate relevant information from publicly available databases through big data technologies and bioinformatics analysis to accelerate the process of non-pharmaceutical-grade drug discovery in bacterial infection research.
-
Synthesis and activity assays. Once identified, the drug candidate is synthesized with laboratory resources and tested for activity to assess the drug's antimicrobial activity.
-
Efficient and customizable. Our non-pharmaceutical drug discovery services are efficient and flexible, allowing for a customized approach to your requirements and delivering results in a reasonable timeline.
Dedicated team support. Our experienced research team, including medicinal chemists, biologists and data scientists, are here to provide you with expert support and advice.
Drug Discovery Services for Diverse Bacteria Infection Research
-
Pseudomonas Aeruginosa Infection
Pseudomonas aeruginosa, one of the hospital infections, often causes pneumonia, skin infections, and sepsis.
-
Streptococcus Pneumoniae Infection
Streptococcus pneumoniae is a common pneumonia-causing organism that can cause severe pneumonia and meningitis.
-
Staphylococcus Aureus Infection
Staphylococcus aureus is a common respiratory and skin pathogen that can cause skin infections and pneumonia.
-
Escherichia coli Infection
E. coli is a common intestinal pathogen that can cause diarrhea and urinary tract infections.
Klebsiella, as one of the hospital-acquired bacteria, often causes pneumonia and urinary tract infections. Liver abscess.
Fig. 1 Typical antibiotic medication development process.1
Creative Biolabs can offer best-in-class non-pharmaceutical grade drug discovery services for common bacteria infection research to help you accelerate the process and contribute to antimicrobial therapy. Please contact us to obtain the services.
Reference:
-
Blaskovich, Mark AT, Mark S. Butler, and Matthew A. Cooper. "Polishing the tarnished silver bullet: the quest for new antibiotics." Essays in biochemistry 61.1 (2017): 103-114.
For Research Use Only. We do not provide direct services or products for patients.
Related Services:
